SOLID TUMOR

This early-stage study tested a new drug called CPO-100 in 34 adults with advanced solid tumors that had not responded to at least two prior treatments. The main goals were to check the drug's safety and find the right dose. The study was stopped early, so results are limited.

This early-phase study tested a new treatment called VAXINIA (a virus designed to attack cancer cells) in 66 adults with advanced solid tumors that had spread. The virus was given alone or with an immunotherapy drug (pembrolizumab), either as a shot into the tumor or through an I…

This early-phase study tested a new daily pill, NKT3447, in 23 adults with advanced solid tumors (like ovarian, endometrial, or lung cancer) that had stopped responding to standard treatments. The goal was to check safety and find the right dose. The study was stopped early, so r…

This study tested a combination of two drugs (rucaparib and atezolizumab) in 130 adults with advanced solid tumors that had DNA repair defects or were sensitive to platinum chemotherapy. The goal was to see if the combo could shrink tumors. The trial was terminated early, so resu…

This study tested a daily pill called AB-106 in people with advanced solid tumors that have a specific gene change (NTRK fusion). The goal was to see if the drug could shrink tumors. Only 14 people took part before the study was stopped early. The drug was given until the cancer …

This early-phase study tested a new drug called WBC100 in 68 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study was stopped early, and it does not offer a cure—it aims to contro…

This study tested an experimental drug called REC-4881 in 18 adults aged 55+ with advanced solid tumors that have AXIN1 or APC gene mutations. The goal was to see if the drug is safe and shrinks tumors. The trial was stopped early, so results are limited.

This early-phase study tested a lab-modified virus called ASP1012 designed to infect and kill cancer cells while leaving healthy cells alone. It also helps the immune system recognize and attack the cancer. The study included 15 adults with advanced solid tumors who had exhausted…

This study tested a new drug called LY3405105 in 54 people with advanced solid tumors that had spread. The main goal was to check the drug's safety and find the right dose. The trial was stopped early, so we have limited information on how well it worked.

This study tested a drug called tovorafenib in people aged 12 and older whose cancers had returned or worsened and had certain gene changes (MAPK pathway). The goal was to see if the drug could shrink tumors. The study was stopped early, so results are limited.

This early-phase trial tested a new cell therapy called ALPP CAR-T in 5 adults with advanced solid tumors that had not responded to standard treatments. The goal was to see if the therapy is safe and can shrink tumors. The study was terminated early, so results are limited.

This early-stage trial tested a personalized treatment called GT201 for people with advanced solid tumors that had spread or come back. The therapy uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy an…

This study tested the drug niraparib in 22 adults with advanced solid tumors (like breast, lung, or pancreatic cancer) that have a specific PALB2 gene mutation. The goal was to see if the drug could shrink tumors or slow cancer growth. The study was stopped early, so results are …

This early-stage study tested a new drug called BGB-3245 in 109 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and see if it could shrink tumors. The study was terminated early, so results are limited.

This early-phase study tested a combination of two experimental drugs (tuvusertib and PLX038) in people with advanced solid tumors that could not be cured. The goal was to find a safe dose and see if the drugs could shrink tumors. Only 10 people were enrolled before the study was…

This study tested a new drug called CX-072 combined with other cancer treatments for adults with solid tumors or advanced melanoma. The goal was to see if the combination shrank tumors. However, the study was stopped early and only enrolled 3 people, so no clear results are avail…

This study tested a new drug called OMX-0407 in 68 people with advanced solid tumors that had stopped responding to other treatments. The goal was to find a safe dose and see if the drug could shrink tumors. The trial was ended early, and results are not yet available.

This early-phase study tested a personalized therapy called GT201 for people with advanced solid tumors that have spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are grown in a lab and given back along with chemotherapy a…

This early-stage study tested a new drug called BGB-A3055, alone or with another drug (tislelizumab), in people with advanced or metastatic solid tumors. The goal was to check safety, how the body handles the drug, and any early signs of tumor shrinkage. The study was stopped ear…

This early-stage study tested an experimental drug called KD033 (SAR445710) in 45 adults with advanced or spreading solid tumors. The main goal was to check the drug's safety at different doses and see if it could shrink tumors. The study was terminated early, so results are limi…

This early-stage trial tested a new drug called ACTM-838 in 10 people with advanced solid tumors that had stopped responding to standard treatments. The study aimed to find a safe dose and check for side effects. The trial was terminated early, so results are limited.

This trial tested a treatment that uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack advanced solid tumors. The goal was to see if it was safe and tolerable. Only 2 people took part before the study was stopped early.

This early-stage study tested a new experimental drug called BGB-R046, given alone or with another drug (tislelizumab), in 42 people with advanced or spreading solid tumors that had not responded to standard treatments. The main goals were to check safety, find the best dose, and…

This early-stage trial tested a new drug called MRTX0902, alone or with another drug (adagrasib), in 64 people with advanced solid tumors (like lung or colon cancer) that have specific KRAS gene mutations. The main goals were to check safety and find the right dose. The study was…

This early-stage trial tested a new oral drug, BBI-825, in 19 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could help control the cancer when used alone or with other targeted therapies.…

This study tested a new drug called IBI3004 in people with advanced solid tumors that had spread or could not be removed by surgery. The goal was to find the safest dose and check for side effects. Only 5 people took part before the study was stopped early.

This early-stage study tested a new drug called TAS2940 in 29 people with advanced solid tumors (like lung, breast, or brain cancer) that had certain genetic changes (EGFR or HER2). The goal was to find a safe dose and see if it could shrink tumors. The trial was stopped early, s…

This study tested a drug called tazemetostat in people with advanced solid tumors that have a specific genetic change (ARID1A mutation). The drug works by blocking a protein (EZH2) that helps these tumors grow. The trial aimed to see if the drug could shrink tumors or stop them f…

This study tested a new drug called BNT142 in people with advanced solid tumors that have a specific protein called CLDN6. The goal was to see if the drug is safe and if it can shrink tumors. The study was stopped early, but the information gathered helps researchers understand h…

This early-phase study tested a new drug called LB4330 in 40 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells by targeting a protein called Claudin 18.2. The main goals were to…

This study tested a new type of PET scan (68Ga-MY6349) to see if it could find thyroid cancer that has come back or spread. It involved 149 adults with different types of thyroid cancer. The goal was to compare this new scan with the standard 18F-FDG PET/CT to see which one detec…